Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

H Dohner; D Weber; J Krzykalla; W Fiedler; MWM Kuhn; T Schroeder; K Mayer; M Lubbert; M Wattad; K Gotze; L Fransecky; E Koller; G Wulf; J Schleicher; M Ringhoffer; Richard Greil; B Hertenstein; J Krauter; UM Martens; D Nachbaur; M Abu Samra; S Machherndl-Spandl; N Basara; C Leis; A Schrade; S Kapp-Schwoerer; L Bullinger; FR Thol; M Heuser; P Paschka; VI Gaidzik; M Saadati; A Benner; RF Schlenk; K Dohner; A Ganser

doi:10.1182/blood-2022-166084

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

H Dohner, D Weber, J Krzykalla, W Fiedler, MWM Kuhn, T Schroeder, K Mayer, M Lubbert, M Wattad, K Gotze, L Fransecky, E Koller, G Wulf, J Schleicher, M Ringhoffer, Richard Greil, B Hertenstein, J Krauter, UM Martens, D NachbaurM Abu Samra, S Machherndl-Spandl, N Basara, C Leis, A Schrade, S Kapp-Schwoerer, L Bullinger, FR Thol, M Heuser, P Paschka, VI Gaidzik, M Saadati, A Benner, RF Schlenk, K Dohner, A Ganser

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

1 Citation (Web of Science)

Original language	English
Pages (from-to)	2010-2013
Journal	BLOOD
Volume	140
DOIs	https://doi.org/10.1182/blood-2022-166084
Publication status	Published - 2022
Event	64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - New Orleans, LA Duration: 10 Dec 2022 → 13 Dec 2022

Access to Document

10.1182/blood-2022-166084

Cite this

Dohner, H., Weber, D., Krzykalla, J., Fiedler, W., Kuhn, MWM., Schroeder, T., Mayer, K., Lubbert, M., Wattad, M., Gotze, K., Fransecky, L., Koller, E., Wulf, G., Schleicher, J., Ringhoffer, M., Greil, R., Hertenstein, B., Krauter, J., Martens, UM., ... Ganser, A. (2022). Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia. BLOOD , 140, 2010-2013. https://doi.org/10.1182/blood-2022-166084

Dohner, H ; Weber, D ; Krzykalla, J et al. / Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia. In: BLOOD 2022 ; Vol. 140. pp. 2010-2013.

@article{252160a113944993be802ac45f3fe056,

title = "Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia",

author = "H Dohner and D Weber and J Krzykalla and W Fiedler and MWM Kuhn and T Schroeder and K Mayer and M Lubbert and M Wattad and K Gotze and L Fransecky and E Koller and G Wulf and J Schleicher and M Ringhoffer and Richard Greil and B Hertenstein and J Krauter and UM Martens and D Nachbaur and {Abu Samra}, M and S Machherndl-Spandl and N Basara and C Leis and A Schrade and S Kapp-Schwoerer and L Bullinger and FR Thol and M Heuser and P Paschka and VI Gaidzik and M Saadati and A Benner and RF Schlenk and K Dohner and A Ganser",

year = "2022",

doi = "10.1182/blood-2022-166084",

language = "English",

volume = "140",

pages = "2010--2013",

journal = "BLOOD ",

issn = "0006-4971",

publisher = "American Society of Hematology ",

note = "64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) ; Conference date: 10-12-2022 Through 13-12-2022",

}

Dohner, H, Weber, D, Krzykalla, J, Fiedler, W, Kuhn, MWM, Schroeder, T, Mayer, K, Lubbert, M, Wattad, M, Gotze, K, Fransecky, L, Koller, E, Wulf, G, Schleicher, J, Ringhoffer, M, Greil, R, Hertenstein, B, Krauter, J, Martens, UM, Nachbaur, D, Abu Samra, M, Machherndl-Spandl, S, Basara, N, Leis, C, Schrade, A, Kapp-Schwoerer, S, Bullinger, L, Thol, FR, Heuser, M, Paschka, P, Gaidzik, VI, Saadati, M, Benner, A, Schlenk, RF, Dohner, K & Ganser, A 2022, 'Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia', BLOOD , vol. 140, pp. 2010-2013. https://doi.org/10.1182/blood-2022-166084

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia. / Dohner, H; Weber, D; Krzykalla, J et al.
In: BLOOD , Vol. 140, 2022, p. 2010-2013.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

AU - Dohner, H

AU - Weber, D

AU - Krzykalla, J

AU - Fiedler, W

AU - Kuhn, MWM

AU - Schroeder, T

AU - Mayer, K

AU - Lubbert, M

AU - Wattad, M

AU - Gotze, K

AU - Fransecky, L

AU - Koller, E

AU - Wulf, G

AU - Schleicher, J

AU - Ringhoffer, M

AU - Greil, Richard

AU - Hertenstein, B

AU - Krauter, J

AU - Martens, UM

AU - Nachbaur, D

AU - Abu Samra, M

AU - Machherndl-Spandl, S

AU - Basara, N

AU - Leis, C

AU - Schrade, A

AU - Kapp-Schwoerer, S

AU - Bullinger, L

AU - Thol, FR

AU - Heuser, M

AU - Paschka, P

AU - Gaidzik, VI

AU - Saadati, M

AU - Benner, A

AU - Schlenk, RF

AU - Dohner, K

AU - Ganser, A

PY - 2022

Y1 - 2022

U2 - 10.1182/blood-2022-166084

DO - 10.1182/blood-2022-166084

M3 - Abstract (Journal)

SN - 0006-4971

VL - 140

SP - 2010

EP - 2013

JO - BLOOD

JF - BLOOD

T2 - 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)

Y2 - 10 December 2022 through 13 December 2022

ER -

Dohner H, Weber D, Krzykalla J, Fiedler W, Kuhn MWM, Schroeder T et al. Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia. BLOOD . 2022;140:2010-2013. doi: 10.1182/blood-2022-166084